RETATRUTIDE
$
469 AUD
Product Info
Retatrutide is a synthetic peptide research compound investigated for its multi-receptor activity across the GLP-1, GIP, and glucagon pathways. It is commonly used in controlled laboratory studies to explore metabolic signalling, receptor interactions, and endocrine regulation. Retatrutide is of interest for research into energy balance, glucose metabolism, and peptide-based therapeutic mechanisms. This compound is supplied strictly for research purposes only and is not intended for human or veterinary use.
Buy 3 and save 15%
Buy 5 and save 20%
Categories
Bacteriostatic Water
AOD
Cagrilintide
Cagrilintide + Semaglutide
Retatrutide
Semaglutide
Tirzepatide
SLU PP 332
MOTS C
BPC 157
bpc-157-tb-500
Description
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Retatrutide is a synthetic triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, designed for synergistic metabolic effects exceeding dual agonist therapies. The peptide targets complementary pathways regulating glucose homeostasis, appetite suppression, and energy expenditure. Retatrutide is extensively studied for its potential in supporting body weight reduction, glucose control, and metabolic health with enhanced efficacy compared to GLP-1 monotherapy or GLP-1/GIP dual agonists. Research indicates the triple agonist approach provides superior weight loss, improved insulin sensitivity, and enhanced energy expenditure through coordinated activation of three metabolic receptor systems. Retatrutide represents a valuable research tool for investigating triple receptor signaling, synergistic metabolic effects, and therapeutic approaches to obesity and type 2 diabetes.
Overview
Retatrutide is a synthetic triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, designed for synergistic metabolic effects exceeding dual agonist therapies. The peptide targets complementary pathways regulating glucose homeostasis, appetite suppression, and energy expenditure. Retatrutide is extensively studied for its potential in supporting body weight reduction, glucose control, and metabolic health with enhanced efficacy compared to GLP-1 monotherapy or GLP-1/GIP dual agonists. Research indicates the triple agonist approach provides superior weight loss, improved insulin sensitivity, and enhanced energy expenditure through coordinated activation of three metabolic receptor systems. Retatrutide represents a valuable research tool for investigating triple receptor signaling, synergistic metabolic effects, and therapeutic approaches to obesity and type 2 diabetes.
Biochemical Characteristics
Retatrutide is a modified peptide engineered to activate GLP-1 receptor, GIP receptor, and glucagon receptor with balanced agonist activity at each receptor. Molecular weight approximately 4,400 Da. The peptide structure incorporates fatty acid modifications enabling albumin binding and extended serum half-life. The peptide is water-soluble with stability across physiological pH ranges (6.5–8.0). Retatrutide demonstrates extended biological half-life due to albumin binding and resistance to enzymatic degradation. The peptide shows selective agonist activity at all three target receptors without significant off-target effects. Cellular uptake occurs through distinct GLP-1, GIP, and glucagon receptor pathways on pancreatic, gastrointestinal, hepatic, and central nervous system tissues, enabling comprehensive metabolic regulation.
Biochemical Characteristics
Retatrutide is a modified peptide engineered to activate GLP-1 receptor, GIP receptor, and glucagon receptor with balanced agonist activity at each receptor. Molecular weight approximately 4,400 Da. The peptide structure incorporates fatty acid modifications enabling albumin binding and extended serum half-life. The peptide is water-soluble with stability across physiological pH ranges (6.5–8.0). Retatrutide demonstrates extended biological half-life due to albumin binding and resistance to enzymatic degradation. The peptide shows selective agonist activity at all three target receptors without significant off-target effects. Cellular uptake occurs through distinct GLP-1, GIP, and glucagon receptor pathways on pancreatic, gastrointestinal, hepatic, and central nervous system tissues, enabling comprehensive metabolic regulation.
Research Applications
Body Weight Reduction Investigation of superior weight loss through triple receptor activation and comprehensive appetite/energy regulation. Glucose Control Assessment of enhanced glycemic control and insulin secretion through coordinated GLP-1 and GIP signaling. Energy Expenditure Study of increased metabolic rate and energy expenditure through glucagon receptor-mediated thermogenesis. Type 2 Diabetes Models Investigation of superior glycemic control compared to dual agonist therapies in diabetes research. Metabolic Syndrome Assessment of improvements in multiple metabolic parameters including lipids, inflammation, and adiposity. Hepatic Metabolism Study of glucagon-mediated enhancement of hepatic glucose production regulation and metabolic flexibility. Lipid Metabolism Investigation of improvements in cholesterol profiles and triglycerides through triple agonist effects.
Research Applications
Body Weight Reduction Investigation of superior weight loss through triple receptor activation and comprehensive appetite/energy regulation. Glucose Control Assessment of enhanced glycemic control and insulin secretion through coordinated GLP-1 and GIP signaling. Energy Expenditure Study of increased metabolic rate and energy expenditure through glucagon receptor-mediated thermogenesis. Type 2 Diabetes Models Investigation of superior glycemic control compared to dual agonist therapies in diabetes research. Metabolic Syndrome Assessment of improvements in multiple metabolic parameters including lipids, inflammation, and adiposity. Hepatic Metabolism Study of glucagon-mediated enhancement of hepatic glucose production regulation and metabolic flexibility. Lipid Metabolism Investigation of improvements in cholesterol profiles and triglycerides through triple agonist effects.
Pathway / Mechanistic Context
GLP-1 Receptor Activation Retatrutide activates GLP-1 receptors on beta cells and intestinal L-cells, enhancing glucose-dependent insulin secretion and slowing gastric emptying for improved postprandial glucose control. GIP Receptor Signaling The peptide activates GIP receptors on beta cells and adipocytes, enhancing insulin secretion and modulating adipose tissue metabolism and energy storage. Glucagon Receptor Agonism Retatrutide activates glucagon receptors on hepatic tissue and brown adipose tissue, enhancing hepatic glucose output regulation and increasing energy expenditure through thermogenesis. Central Appetite Suppression The peptide activates receptors in hypothalamic appetite centers through all three pathways, providing redundant and synergistic appetite suppression superior to dual agonists. Metabolic Flexibility Enhancement Coordinated activation of all three receptors enhances metabolic switching between glucose and lipid oxidation, improving metabolic adaptation to nutrient availability. Energy Expenditure Amplification Triple agonism enables simultaneous reduction of caloric intake (GLP-1/GIP effects) and increase in energy expenditure (glucagon effects), creating superior weight loss trajectory.
Pathway / Mechanistic Context
GLP-1 Receptor Activation Retatrutide activates GLP-1 receptors on beta cells and intestinal L-cells, enhancing glucose-dependent insulin secretion and slowing gastric emptying for improved postprandial glucose control. GIP Receptor Signaling The peptide activates GIP receptors on beta cells and adipocytes, enhancing insulin secretion and modulating adipose tissue metabolism and energy storage. Glucagon Receptor Agonism Retatrutide activates glucagon receptors on hepatic tissue and brown adipose tissue, enhancing hepatic glucose output regulation and increasing energy expenditure through thermogenesis. Central Appetite Suppression The peptide activates receptors in hypothalamic appetite centers through all three pathways, providing redundant and synergistic appetite suppression superior to dual agonists. Metabolic Flexibility Enhancement Coordinated activation of all three receptors enhances metabolic switching between glucose and lipid oxidation, improving metabolic adaptation to nutrient availability. Energy Expenditure Amplification Triple agonism enables simultaneous reduction of caloric intake (GLP-1/GIP effects) and increase in energy expenditure (glucagon effects), creating superior weight loss trajectory.
Preclinical Research Summary
Retatrutide is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with triple agonist peptide structure verification, amino acid analysis, fatty acid acylation verification, and microbial sterility/endotoxin testing. Bioassay verification of triple receptor agonist activity available upon request. Certificate of Analysis provided with each lot.
Preclinical Research Summary
Retatrutide is supplied as sterile aqueous solution or lyophilized powder at concentrations of 1–10 mg/mL. Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC purity verification (≥95%), HPLC-MS molecular confirmation with triple agonist peptide structure verification, amino acid analysis, fatty acid acylation verification, and microbial sterility/endotoxin testing. Bioassay verification of triple receptor agonist activity available upon request. Certificate of Analysis provided with each lot.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
© Standard BioLabs. All rights reserved.